Triplet vs. doublet drug regimens for managing multiple myeloma.

about

Triplet vs. doublet drug regimens for managing multiple myeloma.

Item

http://www.wikidata.org/entity/Q47770089

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Triplet vs. doublet drug regimens for managing multiple myeloma.

@en

Triplet vs. doublet drug regimens for managing multiple myeloma.

@nl

type

Item

label

Triplet vs. doublet drug regimens for managing multiple myeloma.

@en

Triplet vs. doublet drug regimens for managing multiple myeloma.

@nl

prefLabel

Triplet vs. doublet drug regimens for managing multiple myeloma.

@en

Triplet vs. doublet drug regimens for managing multiple myeloma.

@nl

P1476

Triplet vs. doublet drug regimens for managing multiple myeloma

@en

P2093

Laura Corvatta

http://www.w3.org/2001/XMLSchema#string

Silvia Gentili

http://www.w3.org/2001/XMLSchema#string

P2860

The Role of Panobinostat Plus Bortezomib and Dexamethasone in Treating Relapsed or Relapsed and Refractory Multiple Myeloma: A European Perspective

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program.

Superiority of the triple combination of bortezomib-thalidomide-dexamethasone over the dual combination of thalidomide-dexamethasone in patients with multiple myeloma progressing or relapsing after autologous transplantation: the MMVAR/IFM 2005-04 R

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma

PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma.

Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study.

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

P304

137-149

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/14656566.2017.1418856

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Massimo Offidani

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29265901

http://www.w3.org/2001/XMLSchema#string